Coral Laboratories Limited announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, revealing a challenging performance with significant declines in both revenue and profitability. The Board of Directors approved these results during their meeting held on February 13, 2026.

Quarterly Financial Performance

The company's Q3FY26 performance showed substantial year-over-year declines across key financial metrics. Revenue from operations decreased to ₹2156.42 lakhs compared to ₹2298.61 lakhs in Q3FY25, marking a 6.19% decline.

Cost Structure and Operational Metrics

The company's cost structure revealed mixed trends during the quarter. Cost of materials consumed increased significantly to ₹1293.10 lakhs from ₹898.16 lakhs in Q3FY25, representing a 43.98% rise. However, the company benefited from a favorable change in inventories, recording a decrease of ₹500.00 lakhs compared to an increase of ₹32.30 lakhs in the previous year.

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, showed even more pronounced declines. Revenue from operations dropped 31.60% to ₹5942.04 lakhs from ₹8687.06 lakhs in the corresponding period of the previous year. Net profit for the nine-month period declined 47.70% to ₹1115.74 lakhs compared to ₹2132.86 lakhs in the previous year.

Financial Position and Other Details

The company maintained its paid-up equity share capital at ₹357.26 lakhs with a face value of ₹10 per share throughout the reporting periods. Total comprehensive income for Q3FY26 was ₹76.02 lakhs compared to ₹739.78 lakhs in Q3FY25, reflecting the impact of other comprehensive income adjustments.

Coral Laboratories operates in a single business segment of "Formulations" and does not have any subsidiary, associate, or joint venture companies. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors S.C. Mehra & Associates LLP conducting a limited review of the results.

Coral Laboratories has announced a key personnel change with the resignation of Mrs. Dhwani Desai from her position as Company Secretary and Compliance Officer. The resignation, submitted to pursue another career opportunity, will take effect from the closure of business hours on January 31, 2026.

Resignation Details

The pharmaceutical company informed BSE Limited on December 30, 2025, about Mrs. Desai's decision to step down from her role. The Board of Directors has accepted her resignation, and she will be relieved from all responsibilities associated with her position at the end of January 2026.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made through a formal communication to BSE Limited, where Coral Laboratories trades under scrip code 524506.

Key Personnel Impact

Following Mrs. Desai's resignation, she will also cease to function as Key Managerial Personnel of the company effective January 31, 2026. The resignation letter and complete details as required under SEBI regulations have been submitted to the stock exchange as part of the mandatory disclosure process.

Company Communication

The formal intimation was signed by Sushma Kadkade, Director and CFO of Coral Laboratories Limited, ensuring proper authorization and compliance with corporate governance requirements. The company has provided all necessary documentation to maintain transparency with stakeholders and regulatory authorities.